Operations

Rubius Therapeutics Appoints Spencer Fisk as Senior Vice President of Manufacturing

February 21, 2018

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Rubius Therapeutics, a biotechnology company pioneering the creation of a new class of extraordinarily active, ready-to-use and life-changing cellular therapies, today announced the appointment of Spencer Fisk as Senior Vice President, Manufacturing. Mr. Fisk brings to Rubius nearly thirty years of pharmaceutical and biotechnology experience. Mr. Fisk joins Rubius from Novartis, where he […]

Dova Pharmaceuticals, Inc. Announces Proposed Offering of Common Stock

February 21, 2018

DURHAM, N.C., Feb. 20, 2018 (GLOBE NEWSWIRE) — Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet need, today announced that it has commenced an underwritten public offering of 2,500,000 shares of its common stock. All of the shares in […]

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

February 21, 2018

COPENHAGEN, Denmark, Feb. 20, 2018 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis. All of the ADSs are being offered by Ascendis. In addition, Ascendis […]

AIT Therapeutics Appoints Two Senior Executives in Research and Clinical Operations

February 21, 2018

NEW YORK, Feb. 20, 2018 (GLOBE NEWSWIRE) — AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, today announced the appointment of two new executive team members. Mark Rimkus joins AIT as Vice President of Clinical Affairs […]

AMRI Appoints Anthony L. Mattacchione to Senior Vice President and Chief Financial Officer

February 21, 2018

WALTHAM, Mass., Feb. 21, 2018 /PRNewswire/ — AMRI, a global pharmaceutical contract research, development and manufacturing organization, today announced the appointment of Anthony (‘Tony’) Mattacchione as senior vice president and chief financial officer, effective April 2, 2018. Mr. Mattacchione succeeds Felicia Ladin, who announced her intention to leave AMRI in December 2017. Mr. Mattacchione has […]

Aimmune Therapeutics Announces Proposed Public Offering of Common Stock

February 21, 2018

BRISBANE, Calif.–(BUSINESS WIRE)–Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has commenced an underwritten public offering of up to $150,000,000 of shares of its common stock. All of the shares to be sold in the offering will be offered by Aimmune. In addition, Aimmune expects […]

Merck and Viralytics Announce Acquisition Agreement, Expanding Merck’s Leading Immuno-Oncology Pipeline

February 21, 2018

KENILWORTH, N.J. & SYDNEY–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Viralytics Limited (ASX: VLA, OTC: VRACY) today announced that the companies have signed a definitive agreement under which it is proposed that Merck, through a subsidiary, will acquire Viralytics, an Australian publicly traded company focused on oncolytic immunotherapy […]

Celgene Receives Antitrust Clearance for Juno Acquisition

February 21, 2018

SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) today announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR”) with respect to the previously announced tender offer by Celgene’s wholly owned subsidiary, Blue Magpie Corporation, for all issued and outstanding shares of common stock of Juno Therapeutics, Inc. (NASDAQ:JUNO) for $87.00 per share, […]

The Dohmen Company to Sell Dohmen Life Science Services Subsidiary to JLL Partners and Water Street Healthcare Partners

February 21, 2018

MILWAUKEE, Feb. 20, 2018 /PRNewswire/ — Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry, and JLL Partners, a leading middle-market private equity firm, have signed a definitive agreement to acquire Dohmen Life Science Services (“DLSS”) from its parent, The Dohmen Company, in a transaction expected to close in March […]

Basilea’s CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors

February 21, 2018

Basel, Switzerland, February 21, 2018 – Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that Chief Executive Officer Ronald Scott will retire after 18 years with the company. Basilea’s Board of Directors has appointed David Veitch, currently Basilea’s Chief Commercial Officer and member of the Management Committee, to succeed Mr. Scott in the role of Chief […]

Envigo appoints Lynn Lewis as Senior Vice President of Global Sales

February 21, 2018

East Millstone, NJ, 21 February 2018 – Envigo, a leading provider of nonclinical contract research services and research models, today announced the appointment of Lynn Lewis to the position of Senior Vice President, Global Sales. She brings extensive knowledge in both science and business to the company through her successful career in pharmaceuticals and leadership […]

Noventure and Laboratorios Salvat enter into agreement to commercialise innovative medical device in Spain and Portugal for rhinitis and rhinosinusitis

February 21, 2018

The agreement will see the global launch of Noventure’s novel nasal mucoprotection product  Barcelona, Spain, February 21, 2018 – Noventure and Laboratorios Salvat, S.A. (Salvat), announce today that they have entered into an agreement in which Salvat will distribute Noventure’s nasal mucoprotection product in Spain and Portugal. The product contains a mucomimetic agent that forms […]

ORIC Pharmaceuticals Announces $50 Million Series C Financing to Support Novel Therapies for Treatment-Resistant Cancers

February 21, 2018

SOUTH SAN FRANCISCO, Calif., Feb. 21, 2018 /PRNewswire/ — ORIC Pharmaceuticals, a clinical-stage oncology company focused on discovery and development of novel therapies against treatment-resistant cancers, announced the completion of a $50 million Series C preferred stock financing. This financing brings the total equity capital the Company has raised to over $119 million. New investors […]

Ashfield launches new commercial model to improve ROI

February 21, 2018

Ashfield, part of UDG Healthcare, a global leader in providing outsourced healthcare services, has announced the launch of a pioneering new commercial model called The Ashfield Solution. In response to global market trends, The Ashfield Solution is an agile, multi-channel engagement model underpinned by a field analytics engine. The proprietary solution addresses the challenges of […]

Phoenix Marketing Solutions Transforms to Phoenix Group

February 20, 2018

NEW PROVIDENCE, NJ (February 15, 2018) — Phoenix Marketing Solutions, a recognized leader in full-service medical communications and speakers bureau management, has announced its rebrand and will officially be known as Phoenix Group. The new company name aligns strategically with Phoenix Group’s core and vision — a multidisciplinary group unified with one common purpose: to transform […]

Marken Appoints New Vice President, Global Quality Assurance

February 20, 2018

RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2018 /PRNewswire/ — Marken is pleased to announce the appointment of Navnit Patel, Ph.D., as Vice President, Global Quality Assurance, effective March 05, 2018. Dr. Patel will focus on enhancing Marken’s industry-leading quality systems and set new standards for the movement and storage of clinical trial materials. Marken’s ongoing […]

Merck Receives Two More Patents for CRISPR Technology

February 20, 2018

DARMSTADT, Germany, Feb. 20, 2018 /PRNewswire/ — Merck, a leading science and technology company and leader in genome editing, today announced that the Korean Intellectual Property Office and the Israel Patent Office have each issued notices granting Merck’s patent applications for the company’s CRISPR technology used in a genomic-integration method for eukaryotic cells.   “These […]

PDL BioPharma Terminates Interest in Pursuing Acquisition of Neos

February 20, 2018

INCLINE VILLAGE, Nev., Feb. 20, 2018 /PRNewswire/ — PDL BioPharma, Inc. (NASDAQ: PDLI) today officially announced it will no longer pursue its proposed acquisition of Neos Therapeutics, Inc. (NASDAQ: NEOS). While PDL’s last public disclosure announced its proposal expired on November 8, 2017, PDL has maintained its interest until recently making the decision to not […]

Adamas Announces Declaratory Judgment Action Filed by Osmotica Related to Approved OSMOLEX ER

February 20, 2018

EMERYVILLE, Calif., Feb. 19, 2018 (GLOBE NEWSWIRE) — Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) announced today that it has learned that Osmotica Pharmaceuticals LLC and Vertical Pharmaceuticals LCC (Osmotica) filed an action in Delaware federal court on February 16, 2018 requesting a declaratory judgment that Osmotica’s newly-approved product OSMOLEX ER™ (amantadine) extended-release tablets does not infringe certain […]

Veritas Intends to Complete the 100% Takeover of Cannevert Therapeutics in Q1

February 20, 2018

VANCOUVER, British Columbia, Feb. 20, 2018 (GLOBE NEWSWIRE) — Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) is pleased to announce the Company and its research arm, Cannevert Therapeutics Ltd. (“CTL”), are in process of obtaining a Fairness Opinion from Davidson & Company LLP (“Davidson”) of Vancouver, Canada regarding Veritas’ planned takeover of […]

Dynavax Secures $175 Million in Non-Dilutive Debt Financing

February 20, 2018

BERKELEY, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) — Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that it has closed on a $175 million non-dilutive term loan agreement with CRG LP, a healthcare focused investment firm. Dynavax will receive $100 million in a first tranche and up to an additional $75 million may be borrowed in a […]

Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases

February 20, 2018

Cambridge, Ma., Redmond, Wash., and Brussels, Belgium – February 20, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG), Microsoft and EURORDIS-Rare Diseases Europe today announced a strategic alliance to address the diagnostic challenge for patients living with a rare disease. The long road to diagnosis is one of the most important issues affecting the health, […]

FEEDBACK